Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension

PHASE4RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 5, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Sotatercept

As per FDA indications, sotatercept will be administered as 0.3 mg/kg injection for the first dose followed by 0.7 mg/kg injections for subsequent doses.

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER